INR 105.3
(1.4%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 35.36 Million INR | 154.32% |
2022 | -65.09 Million INR | -252.38% |
2021 | 42.72 Million INR | 365.35% |
2020 | -16.1 Million INR | 64.72% |
2019 | -45.63 Million INR | -400.68% |
2018 | 15.17 Million INR | -73.77% |
2017 | 57.87 Million INR | -30.57% |
2016 | 83.35 Million INR | -62.18% |
2015 | 220.42 Million INR | 150.6% |
2014 | -435.66 Million INR | -544.98% |
2013 | 97.9 Million INR | -28.62% |
2012 | 137.15 Million INR | 32.35% |
2011 | 103.63 Million INR | 23.9% |
2010 | 83.63 Million INR | 19.06% |
2009 | 70.24 Million INR | -48.77% |
2008 | 137.13 Million INR | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | - INR | -100.0% |
2023 Q1 | 821.82 Million INR | 1362.42% |
2023 Q4 | 35.36 Million INR | -96.53% |
2023 Q3 | 1.02 Billion INR | 12071.05% |
2023 Q2 | -8.52 Million INR | -101.04% |
2023 FY | 35.36 Million INR | 154.32% |
2022 Q1 | 712.04 Million INR | 1566.69% |
2022 Q2 | 102.59 Million INR | -85.59% |
2022 Q3 | 701.99 Million INR | 584.21% |
2022 FY | -65.09 Million INR | -252.38% |
2022 Q4 | -65.09 Million INR | -109.27% |
2021 Q4 | 42.72 Million INR | -93.04% |
2021 FY | 42.72 Million INR | 365.35% |
2021 Q1 | 512.02 Million INR | 3280.29% |
2021 Q2 | 16.68 Million INR | -96.74% |
2021 Q3 | 614.16 Million INR | 3580.92% |
2020 FY | -16.1 Million INR | 64.72% |
2020 Q1 | 478.35 Million INR | 1148.25% |
2020 Q3 | 499.88 Million INR | 2044.6% |
2020 Q2 | -25.7 Million INR | -105.37% |
2020 Q4 | -16.1 Million INR | -103.22% |
2019 FY | -45.63 Million INR | -400.68% |
2019 Q3 | 391.7 Million INR | 1846.57% |
2019 Q4 | -45.63 Million INR | -111.65% |
2019 Q1 | 329.75 Million INR | 2072.75% |
2019 Q2 | -22.42 Million INR | -106.8% |
2018 Q4 | 15.17 Million INR | 0.0% |
2018 FY | 15.17 Million INR | -73.77% |
2018 Q1 | 178.71 Million INR | 0.0% |
2017 FY | 57.87 Million INR | -30.57% |
2016 FY | 83.35 Million INR | -62.18% |
2015 Q2 | -318.23 Million INR | 0.0% |
2015 FY | 220.42 Million INR | 150.6% |
2014 Q1 | 104.61 Million INR | 6.85% |
2014 FY | -435.66 Million INR | -544.98% |
2014 Q3 | 81.63 Million INR | -36.44% |
2014 Q2 | 128.43 Million INR | 22.77% |
2014 Q4 | -435.66 Million INR | -633.67% |
2013 Q1 | 5.27 Million INR | -96.16% |
2013 FY | 97.9 Million INR | -28.62% |
2013 Q3 | 101.43 Million INR | -12.88% |
2013 Q2 | 116.43 Million INR | 2108.08% |
2013 Q4 | 97.9 Million INR | -3.48% |
2012 FY | 137.15 Million INR | 32.35% |
2012 Q4 | 137.15 Million INR | 0.0% |
2011 FY | 103.63 Million INR | 23.9% |
2011 Q4 | 103.63 Million INR | 0.0% |
2010 FY | 83.63 Million INR | 19.06% |
2009 FY | 70.24 Million INR | -48.77% |
2008 FY | 137.13 Million INR | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 3.86 Billion INR | 99.085% |
Aurobindo Pharma Limited | 3.69 Billion INR | 99.043% |
Glenmark Life Sciences Limited | -2.84 Billion INR | 101.244% |
Granules India Limited | 9.28 Billion INR | 99.619% |
Indoco Remedies Limited | 6.47 Billion INR | 99.454% |
Achyut Healthcare Limited | -3.74 Million INR | 1044.02% |
Ajanta Pharma Limited | -954.9 Million INR | 103.703% |
Alkem Laboratories Limited | -1.6 Billion INR | 102.197% |
Brooks Laboratories Limited | 49.48 Million INR | 28.538% |
AstraZeneca Pharma India Limited | -5.01 Billion INR | 100.706% |
Bajaj HealthCare Limited | 3.29 Billion INR | 98.928% |
Bliss GVS Pharma Limited | -1.15 Billion INR | 103.054% |
Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 99.726% |
Eris Lifesciences Limited | 13.8 Billion INR | 99.744% |
FDC Limited | -57.75 Million INR | 161.233% |
Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 100.825% |
Gufic Biosciences Limited | 3.19 Billion INR | 98.893% |
Ind-Swift Laboratories Limited | -4.15 Billion INR | 100.851% |
Ipca Laboratories Limited | 11.41 Billion INR | 99.69% |
Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 102.544% |
Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 98.17% |
Lasa Supergenerics Limited | 205.79 Million INR | 82.817% |
Laurus Labs Limited | 24.38 Billion INR | 99.855% |
Lupin Limited | 17.19 Billion INR | 99.794% |
Mankind Pharma Limited | -9.9 Billion INR | 100.357% |
Medicamen Biotech Limited | 160.31 Million INR | 77.942% |
Medico Remedies Limited | 78.67 Million INR | 55.053% |
Megasoft Limited | 1.28 Billion INR | 97.249% |
NATCO Pharma Limited | -5.81 Billion INR | 100.608% |
Piramal Pharma Limited | 42.27 Billion INR | 99.916% |
RPG Life Sciences Limited | -364.7 Million INR | 109.696% |
Sigachi Industries Limited | 859.94 Million INR | 95.888% |
Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.049% |
Suven Pharmaceuticals Limited | 144.97 Million INR | 75.608% |
Syncom Formulations (India) Limited | 46.21 Million INR | 23.475% |
Unichem Laboratories Limited | 931.91 Million INR | 96.205% |
Wanbury Limited | 1.1 Billion INR | 96.802% |
Windlas Biotech Limited | -273.04 Million INR | 112.952% |
ZIM Laboratories Limited | 983.6 Million INR | 96.405% |
Zydus Lifesciences Limited | 3.91 Billion INR | 99.096% |
Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 103.755% |
Divi's Laboratories Limited | -39.77 Billion INR | 100.089% |
Hester Biosciences Limited | 2.29 Billion INR | 98.456% |
Procter & Gamble Health Limited | -2.34 Billion INR | 101.506% |
Amrutanjan Health Care Limited | -248.79 Million INR | 114.214% |
Bal Pharma Limited | 1.26 Billion INR | 97.201% |
Strides Pharma Science Limited | 23.25 Billion INR | 99.848% |
Venus Remedies Limited | -267.7 Million INR | 113.21% |
Aarti Pharmalabs Limited | 2.61 Billion INR | 98.646% |
Nectar Lifesciences Limited | 6.15 Billion INR | 99.426% |
Shilpa Medicare Limited | 9.06 Billion INR | 99.61% |
Aarti Drugs Limited | 5.54 Billion INR | 99.363% |
IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 103.211% |
Suven Life Sciences Limited | -1.63 Billion INR | 102.166% |
Ind-Swift Limited | 9.5 Billion INR | 99.628% |
Valiant Laboratories Limited | -295.03 Million INR | 111.986% |
J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 98.747% |
Solara Active Pharma Sciences Limited | 10.02 Billion INR | 99.647% |
Themis Medicare Limited | 764.96 Million INR | 95.377% |
Hikal Limited | 7.96 Billion INR | 99.556% |
Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.889% |
Sequent Scientific Limited | 4.17 Billion INR | 99.154% |
Novartis India Limited | -5.89 Billion INR | 100.6% |
Wockhardt Limited | 18.27 Billion INR | 99.806% |
Jubilant Pharmova Limited | 27.07 Billion INR | 99.869% |
Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 291.711% |
Neuland Laboratories Limited | -214.05 Million INR | 116.52% |
Morepen Laboratories Limited | -231.17 Million INR | 115.297% |
Kilitch Drugs (India) Limited | 120.03 Million INR | 70.54% |
Mangalam Drugs & Organics Limited | 975.81 Million INR | 96.376% |